Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription Articles published in J Virol Retrieve available abstracts of 121 articles: HTML format

Single Articles

October 2025
1. LAI DC, Nguyen TN, Trinh GP, Steffen D, et al
   Lipid nanoparticle-encapsulated DNA vaccine induces balanced antibody and T-cell responses in pigs with maternally derived antibodies.
   J Virol. 2025 Oct 9:e0112325. doi: 10.1128/jvi.01123.
   PubMed     Abstract available
   
   
   
2. BESSEY TK, Wang Y, Moon S-S, Sanchez-Tacuba L, et al
   Mutations of two amino acids in VP5 mediate the attenuation of human rotavirus vaccine: evidence from in vitro and in vivo studies.
   J Virol. 2025 Oct 8:e0106725. doi: 10.1128/jvi.01067.
   PubMed     Abstract available
   
   
   
3. PAN Z, Jiang L, Chen Y, Peng H, et al
   Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations.
   J Virol. 2025 Oct 3:e0109925. doi: 10.1128/jvi.01099.
   PubMed     Abstract available
   
   
   September 2025
4. SUN L, Huang M, Feng S, Zhang W, et al
   Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses.
   J Virol. 2025 Sep 30:e0120925. doi: 10.1128/jvi.01209.
   PubMed     Abstract available
   
   
   
5. ZHOU J, Cai S, Huang H, Yang F, et al
   LPS/TLR4-activated M1-polarized macrophage-derived exosomes enhance IBV vaccine efficacy in chickens.
   J Virol. 2025 Sep 23:e0115625. doi: 10.1128/jvi.01156.
   PubMed     Abstract available
   
   
   
6. PENG G, Zhao X, Zou X, Zhang H, et al
   An attenuated African swine fever virus with deletions of the CD2v and A137R genes offers complete protection against homologous challenge in pigs.
   J Virol. 2025;99:e0026225.
   PubMed     Abstract available
   
   
   
7. QU Y, Li J, Deng H, Wang Y, et al
   Viroporins: emerging viral infection mechanisms and therapeutic targets.
   J Virol. 2025;99:e0103825.
   PubMed     Abstract available
   
   
   
8. PAPPAS C, Brock N, Belser JA, Kieran TJ, et al
   Identification of clinical and virological correlates associated with influenza A candidate vaccine virus (CVV) attenuation in a ferret model.
   J Virol. 2025 Sep 17:e0102325. doi: 10.1128/jvi.01023.
   PubMed     Abstract available
   
   
   
9. CAO M, Li Y, Song X, Lu Z, et al
   Broad-spectrum vaccines against various and evolving viruses: from antigen design to nanoparticle delivery.
   J Virol. 2025 Sep 12:e0099725. doi: 10.1128/jvi.00997.
   PubMed     Abstract available
   
   
   
10. FAN W, Zeng X, Chen Y, Yu Q, et al
    A recombinant Marek's disease vaccine candidate provides complete protection against infectious bursal disease virus and H9 subtype avian influenza virus in chickens.
    J Virol. 2025 Sep 11:e0114925. doi: 10.1128/jvi.01149.
    PubMed     Abstract available
    
    
    
11. HAGA Y, Babu E P, Swiderska-Syn M, Reagan EK, et al
    Hepatitis C virus modified (S)E2(F442NYT)-mRNA-LNP candidate vaccine promotes helper CXCR5(+)T cells.
    J Virol. 2025 Sep 5:e0135525. doi: 10.1128/jvi.01355.
    PubMed     Abstract available
    
    
    
12. OOM AL, Wilson KK, Yonatan M, Rettig S, et al
    Correction for Oom et al., "The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response".
    J Virol. 2025 Sep 4:e0087225. doi: 10.1128/jvi.00872.
    PubMed    
    
    
    August 2025
13. CHATURBHUJ DN, Sliepen K, Cupo A, Steinberg B, et al
    A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers.
    J Virol. 2025 Aug 27:e0091325. doi: 10.1128/jvi.00913.
    PubMed     Abstract available
    
    
    
14. HU Z, Tian S, Zhou Y, Wang Y, et al
    Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses.
    J Virol. 2025 Aug 26:e0090325. doi: 10.1128/jvi.00903.
    PubMed     Abstract available
    
    
    
15. HE Q, Zou Y, Yu B, Yuan Q, et al
    A novel nanoparticle vaccine, based on S1-CTD, elicits robust protective immune responses against porcine deltacoronavirus.
    J Virol. 2025 Aug 21:e0067425. doi: 10.1128/jvi.00674.
    PubMed     Abstract available
    
    
    
16. LIU J, Xia Y, Tian C, Chen Z, et al
    E2-based mRNA vaccine encapsulated in lipid nanoparticles protects pigs against classical swine fever virus.
    J Virol. 2025 Aug 21:e0097825. doi: 10.1128/jvi.00978.
    PubMed     Abstract available
    
    
    
17. ZHANG H, Deng X, Dai R, Fu J, et al
    Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.
    J Virol. 2025 Aug 21:e0068825. doi: 10.1128/jvi.00688.
    PubMed     Abstract available
    
    
    
18. HU J, Zheng H, Ran W, Wang X, et al
    Mucosal vaccination with long-form TSLP induces migratory cDC1-mediated adaptive immunity against SARS-CoV-2 infection.
    J Virol. 2025 Aug 19:e0123125. doi: 10.1128/jvi.01231.
    PubMed     Abstract available
    
    
    
19. ZHANG C, Zhou Y-C, Song W-Y, Liu X-X, et al
    Rationally designed self-assembled peptide nanofibers provoke robust humoral immunity against nervous necrosis virus.
    J Virol. 2025;99:e0031925.
    PubMed     Abstract available
    
    
    
20. CHIU H-J, Wang H-C, Chang W
    Structural dissection of vaccinia G9 identifies residues essential for membrane fusion and complex assembly.
    J Virol. 2025 Aug 18:e0072325. doi: 10.1128/jvi.00723.
    PubMed     Abstract available
    
    
    
21. GUO S, Ru Y, Zhang H, Xue J, et al
    An African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development.
    J Virol. 2025 Aug 14:e0047825. doi: 10.1128/jvi.00478.
    PubMed     Abstract available
    
    
    
22. DZIMIANSKI JV, Nagashima KA, Cruz JM, Sautto GA, et al
    Assessing the structural boundaries of broadly reactive antibody interactions with diverse H3 influenza hemagglutinin proteins.
    J Virol. 2025 Aug 14:e0045325. doi: 10.1128/jvi.00453.
    PubMed     Abstract available
    
    
    
23. SOWNTHIRARAJAN B, Mason M, Loganathan G, Manivasagam S, et al
    A versatile H5N1-VSV platform for safe influenza virus research applications.
    J Virol. 2025 Aug 8:e0097525. doi: 10.1128/jvi.00975.
    PubMed     Abstract available
    
    
    
24. YU R, Bai Y, Zhang L, Zhou P, et al
    Single self-cleaving mRNA vaccine expressing multiple viral structural proteins elicits robust immune responses and protects nursing piglets against PDCoV infection.
    J Virol. 2025 Aug 6:e0084925. doi: 10.1128/jvi.00849.
    PubMed     Abstract available
    
    
    
25. BAI Y-Z, Xu H, Liu Y-G, Sun Y, et al
    Nsp2 replicase-mediated viral uncoating in porcine alveolar macrophages contributes to the attenuation of PRRSV-2 live attenuated vaccine.
    J Virol. 2025 Aug 4:e0063625. doi: 10.1128/jvi.00636.
    PubMed     Abstract available
    
    
    
26. MBOKO WP, Wang Y, Cao W, Sayedahmed EE, et al
    Trained ILCs confer adaptive immunity-independent protection against influenza.
    J Virol. 2025 Aug 4:e0053225. doi: 10.1128/jvi.00532.
    PubMed     Abstract available
    
    
    July 2025
27. DONG J, Yue Luo S, Smyth S, Melvie G, et al
    The vaccinia virus protein, C16, promotes the ubiquitylation and relocalization of the antiviral E3 ubiquitin-ligase, TRIM25.
    J Virol. 2025 Jul 28:e0089825. doi: 10.1128/jvi.00898.
    PubMed     Abstract available
    
    
    
28. TOHMA K, Ford-Siltz LA, Kendra JA, Parra GI, et al
    Manipulation of immunodominant variable epitopes of norovirus capsid protein elicited cross-blocking antibodies to different GII.4 variants despite the low potency of the polyclonal sera.
    J Virol. 2025;99:e0061125.
    PubMed     Abstract available
    
    
    
29. LEONARD RA, Spurrier MA, Skavicus S, Luo Z, et al
    Development of DNA and mRNA-LNP vaccines against an H5N1 clade 2.3.4.4b influenza virus.
    J Virol. 2025 Jul 16:e0079525. doi: 10.1128/jvi.00795.
    PubMed     Abstract available
    
    
    
30. CARLOCK MA, Pierce SR, Ross TM
    Breadth of antibody activity elicited by an influenza B hemagglutinin vaccine is influenced by pre-existing immune responses to influenza B viruses.
    J Virol. 2025 Jul 15:e0070525. doi: 10.1128/jvi.00705.
    PubMed     Abstract available
    
    
    
31. WINSTON SM, Wiggins KB, Schultz-Cherry S, Davidoff AM, et al
    Teaching an old vector new tricks: the surprising versatility of AAV vaccines.
    J Virol. 2025 Jul 14:e0073025. doi: 10.1128/jvi.00730.
    PubMed     Abstract available
    
    
    
32. HENG W, Zang D, Li R, Jiang Q, et al
    A novel replication-deficient FCV vaccine provides strong immune protection in cats.
    J Virol. 2025 Jul 8:e0009325. doi: 10.1128/jvi.00093.
    PubMed     Abstract available
    
    
    June 2025
33. SONG Q, Yang H, Zhu H, Hu Y, et al
    Hydrophobic residue substitutions enhance the stability and in vivo immunogenicity of respiratory syncytial virus fusion protein.
    J Virol. 2025;99:e0008725.
    PubMed     Abstract available
    
    
    
34. HARRIS C, Kapingidza AB, San JE, Christopher J, et al
    Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes.
    J Virol. 2025 Jun 13:e0046525. doi: 10.1128/jvi.00465.
    PubMed     Abstract available
    
    
    
35. LIU M, Aryal B, Niu X, Wang Q, et al
    Engineering a recombination-resistant live attenuated vaccine candidate with suppressed interferon antagonists for PEDV.
    J Virol. 2025 Jun 12:e0045125. doi: 10.1128/jvi.00451.
    PubMed     Abstract available
    
    
    
36. SCHLEISS MR, Fernandez-Alarcon C, Bierle CJ, Geballe AP, et al
    Replication-deficient whole-virus vaccines against cytomegalovirus induce protective immunity in a guinea pig congenital infection model.
    J Virol. 2025 Jun 11:e0020725. doi: 10.1128/jvi.00207.
    PubMed     Abstract available
    
    
    
37. COGGON A, Lopes S, Simon G, Arendsee Z, et al
    Quantifying the zoonotic risk profile of European influenza A viruses in swine from 2010 to 2020 inclusive.
    J Virol. 2025 Jun 4:e0030625. doi: 10.1128/jvi.00306.
    PubMed     Abstract available
    
    
    May 2025
38. KARTHIGEYAN KP, Connors M, Binuya CR, Gross M, et al
    A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits humoral immunity similar to that of postfusion gB in mice.
    J Virol. 2025 May 8:e0217824. doi: 10.1128/jvi.02178.
    PubMed     Abstract available
    
    
    
39. LUGANO D, Mwangi K, Mware B, Kibet G, et al
    Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population.
    J Virol. 2025 May 6:e0048225. doi: 10.1128/jvi.00482.
    PubMed     Abstract available
    
    
    April 2025
40. LE CTT, Kim K-H, Raha JR, Bhatnagar N, et al
    Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination.
    J Virol. 2025 Apr 23:e0229424. doi: 10.1128/jvi.02294.
    PubMed     Abstract available
    
    
    
41. LI Y, Yang S, Qian J, Liu S, et al
    Molecular characteristics of the immune escape of coronavirus PEDV under the pressure of vaccine immunity.
    J Virol. 2025 Apr 16:e0219324. doi: 10.1128/jvi.02193.
    PubMed     Abstract available
    
    
    
42. THIONO DJ, Samaras D, Phan TTN, Zhu DR, et al
    Stabilized dengue virus 2 envelope subunit vaccine redirects the neutralizing antibody response to all E-domains.
    J Virol. 2025 Apr 16:e0022925. doi: 10.1128/jvi.00229.
    PubMed     Abstract available
    
    
    
43. KAWAKITA T, Sekiya T, Kameda Y, Nomura N, et al
    ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4(+) and CD8(+) T-cell responses and neutralizing antibody induction.
    J Virol. 2025 Apr 15:e0229024. doi: 10.1128/jvi.02290.
    PubMed     Abstract available
    
    
    
44. LOU Y-N, Sun M-X, Li K, Xiong X-C, et al
    A single residue in domain II of envelope protein of yellow fever virus is critical for neutralization sensitivity.
    J Virol. 2025;99:e0177024.
    PubMed     Abstract available
    
    
    
45. CHENTOUFI AA, Prakash S, Vahed H, Karan S, et al
    A tissue-targeted prime/pull/keep therapeutic herpes simplex virus vaccine protects against recurrent ocular herpes infection and disease in HLA-A*0201 transgenic rabbits.
    J Virol. 2025 Apr 10:e0013525. doi: 10.1128/jvi.00135.
    PubMed     Abstract available
    
    
    March 2025
46. BLASS E, Colarusso A, Aid M, Larocca RA, et al
    Early spatiotemporal evolution of the immune response elicited by adenovirus serotype 26 vector vaccination in mice.
    J Virol. 2025 Mar 31:e0024725. doi: 10.1128/jvi.00247.
    PubMed     Abstract available
    
    
    
47. OOM AL, Wilson KK, Yonatan M, Rettig S, et al
    The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response.
    J Virol. 2025 Mar 31:e0025325. doi: 10.1128/jvi.00253.
    PubMed     Abstract available
    
    
    
48. JANA ID, Kanjo K, Roy S, Bhasin M, et al
    Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.
    J Virol. 2025 Mar 26:e0005125. doi: 10.1128/jvi.00051.
    PubMed     Abstract available
    
    
    
49. LI P, Faraone JN, Hsu CC, Chamblee M, et al
    Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.
    J Virol. 2025 Mar 26:e0024225. doi: 10.1128/jvi.00242.
    PubMed     Abstract available
    
    
    
50. BEAVIS AC, Xiao P, Gingerich MC, Briggs K, et al
    A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates.
    J Virol. 2025 Mar 21:e0199024. doi: 10.1128/jvi.01990.
    PubMed     Abstract available
    
    
    
51. BEAVIS AC, Li Z, Briggs K, Gingerich MC, et al
    Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants.
    J Virol. 2025 Mar 21:e0198924. doi: 10.1128/jvi.01989.
    PubMed     Abstract available
    
    
    
52. MLINGO TAM, Theron J, Mokoena NB
    Plasmid DNA-based reverse genetics as a platform for manufacturing of bluetongue vaccine.
    J Virol. 2025 Mar 6:e0013925. doi: 10.1128/jvi.00139.
    PubMed     Abstract available
    
    
    
53. HU H, Zhang Y, Zheng H, Zhao X, et al
    Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response.
    J Virol. 2025 Mar 4:e0232324. doi: 10.1128/jvi.02323.
    PubMed     Abstract available
    
    
    
54. KARL V, Hofmann M, Thimme R
    Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination.
    J Virol. 2025 Mar 3:e0135024. doi: 10.1128/jvi.01350.
    PubMed     Abstract available
    
    
    February 2025
55. ABBO SR, Yan K, Geertsema C, Hick TAH, et al
    Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage.
    J Virol. 2025 Feb 27:e0232224. doi: 10.1128/jvi.02322.
    PubMed     Abstract available
    
    
    
56. KEEP S, Foldes K, Dowgier G, Freimanis G, et al
    Recombinant infectious bronchitis virus containing mutations in non-structural proteins 10, 14, 15, and 16 and within the macrodomain provides complete protection against homologous challenge.
    J Virol. 2025 Feb 27:e0166324. doi: 10.1128/jvi.01663.
    PubMed     Abstract available
    
    
    
57. LI W, Hangalapura BN, van den Elzen P, van den Born E, et al
    Spike gene variability in porcine epidemic diarrhea virus as a determinant for virulence.
    J Virol. 2025 Feb 26:e0216524. doi: 10.1128/jvi.02165.
    PubMed     Abstract available
    
    
    
58. CHEN C-X, Wang X, Su W, Tian Y, et al
    Changes in the dynamic characteristics of G-protein can alter the immune-protection efficacy of rabies virus vaccine.
    J Virol. 2025 Feb 21:e0195424. doi: 10.1128/jvi.01954.
    PubMed     Abstract available
    
    
    
59. PARK H, Kingstad-Bakke B, Cleven T, Jung M, et al
    Diversifying T-cell responses: safeguarding against pandemic influenza with mosaic nucleoprotein.
    J Virol. 2025 Feb 3:e0086724. doi: 10.1128/jvi.00867.
    PubMed     Abstract available
    
    
    January 2025
60. SAMAAN P, Korosec CS, Budylowski P, Chau SLL, et al
    mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-gamma and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.
    J Virol. 2025 Jan 31:e0168524. doi: 10.1128/jvi.01685.
    PubMed     Abstract available
    
    
    
61. ZHAO B, Sun Z, Wang S, Shi Z, et al
    Structural basis of different neutralization capabilities of monoclonal antibodies against H7N9 virus.
    J Virol. 2025;99:e0140024.
    PubMed     Abstract available
    
    
    
62. SADLER HL, Rijal P, Tan TK, Townsend ARM, et al
    A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.
    J Virol. 2025 Jan 27:e0033124. doi: 10.1128/jvi.00331.
    PubMed     Abstract available
    
    
    
63. KENNEDY PGE, Grose C
    Insights into pathologic mechanisms occurring during serious adverse events following live zoster vaccination.
    J Virol. 2025 Jan 17:e0181624. doi: 10.1128/jvi.01816.
    PubMed     Abstract available
    
    
    
64. NAGHIBOSADAT M, Babuadze GG, Pei Y, Hurst J, et al
    Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models.
    J Virol. 2025 Jan 16:e0139024. doi: 10.1128/jvi.01390.
    PubMed     Abstract available
    
    
    
65. DSOUZA L, Pant A, Pope B, Yang Z, et al
    Vaccinia growth factor-dependent modulation of the mTORC1-CAD axis upon nutrient restriction.
    J Virol. 2025 Jan 16:e0211024. doi: 10.1128/jvi.02110.
    PubMed     Abstract available
    
    
    December 2024
66. LV H, Teo QW, Lee C-CD, Liang W, et al
    Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model.
    J Virol. 2024 Dec 5:e0169524. doi: 10.1128/jvi.01695.
    PubMed     Abstract available
    
    
    November 2024
67. LI C, Culhane MR, Schroeder DC, Cheeran MC-J, et al
    Quantifying the impact of vaccination on transmission and diversity of influenza A variants in pigs.
    J Virol. 2024 Nov 12:e0124524. doi: 10.1128/jvi.01245.
    PubMed     Abstract available
    
    
    
68. JIMENEZ-CABELLO L, Utrilla-Trigo S, Rodriguez-Sabando K, Carra-Valenzuela A, et al
    Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(-/-) mice.
    J Virol. 2024 Nov 7:e0168724. doi: 10.1128/jvi.01687.
    PubMed     Abstract available
    
    
    
69. CHEN D, Zhang W, Xiao B, Xu B, et al
    Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
    J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
    PubMed     Abstract available
    
    
    
70. DAI W, Xing M, Sun L, Lv L, et al
    Lipid nanoparticles as adjuvant of norovirus VLP vaccine augment cellular and humoral immune responses in a TLR9- and type I IFN-dependent pathway.
    J Virol. 2024 Nov 4:e0169924. doi: 10.1128/jvi.01699.
    PubMed     Abstract available
    
    
    October 2024
71. PANT A, Brahim Belhaouari D, Dsouza L, Yang Z, et al
    Stimulation of neutral lipid synthesis via viral growth factor signaling and ATP citrate lyase during vaccinia virus infection.
    J Virol. 2024 Oct 30:e0110324. doi: 10.1128/jvi.01103.
    PubMed     Abstract available
    
    
    
72. CAILLAVA AJ, Alfonso V, Tejerina Cibello M, Demaria MA, et al
    A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.
    J Virol. 2024 Oct 23:e0101724. doi: 10.1128/jvi.01017.
    PubMed     Abstract available
    
    
    
73. ZHANG D, Xie Y, Liao Q, Jiao Z, et al
    Development of a safe and broad-spectrum attenuated PEDV vaccine candidate by S2 subunit replacement.
    J Virol. 2024 Oct 15:e0042924. doi: 10.1128/jvi.00429.
    PubMed     Abstract available
    
    
    
74. WANG W, Bhushan G, Paz S, Stauft CB, et al
    Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.
    J Virol. 2024 Oct 4:e0094824. doi: 10.1128/jvi.00948.
    PubMed     Abstract available
    
    
    
75. DO THT, Wille M, Wheatley AK, Koutsakos M, et al
    Triton X-100-treated virus-based ELLA demonstrates discordant antigenic evolution of influenza B virus hemagglutinin and neuraminidase.
    J Virol. 2024 Oct 3:e0118624. doi: 10.1128/jvi.01186.
    PubMed     Abstract available
    
    
    September 2024
76. HAMELE CE, Luo Z, Leonard RA, Spurrier MA, et al
    Headless hemagglutinin-containing influenza viral particles direct immune responses toward more conserved epitopes.
    J Virol. 2024 Sep 26:e0116624. doi: 10.1128/jvi.01166.
    PubMed     Abstract available
    
    
    
77. LOES AN, Tarabi RAL, Huddleston J, Touyon L, et al
    High-throughput sequencing-based neutralization assay reveals how repeated vaccinations impact titers to recent human H1N1 influenza strains.
    J Virol. 2024 Sep 24:e0068924. doi: 10.1128/jvi.00689.
    PubMed     Abstract available
    
    
    
78. SONG X, Li Y, Wang C, Zhao Y, et al
    Efficacy evaluation of a bivalent subunit vaccine against epidemic PEDV heterologous strains with low cross-protection.
    J Virol. 2024 Sep 10:e0130924. doi: 10.1128/jvi.01309.
    PubMed     Abstract available
    
    
    
79. AGRAWAL P, Knudsen ML, MacCamy A, Hurlburt NK, et al
    Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env.
    J Virol. 2024 Sep 6:e0074424. doi: 10.1128/jvi.00744.
    PubMed     Abstract available
    
    
    
80. SOUDANI N, Bricker TL, Darling T, Seehra K, et al
    Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
    J Virol. 2024 Sep 4:e0052824. doi: 10.1128/jvi.00528.
    PubMed     Abstract available
    
    
    August 2024
81. YING B, Liang C-Y, Desai P, Scheaffer SM, et al
    Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
    J Virol. 2024 Aug 28:e0057424. doi: 10.1128/jvi.00574.
    PubMed     Abstract available
    
    
    
82. GOODWIN E, Gibbs JS, Yewdell JW, Eisenlohr LC, et al
    Influenza virus antibodies inhibit antigen-specific de novo B cell responses in mice.
    J Virol. 2024 Aug 28:e0076624. doi: 10.1128/jvi.00766.
    PubMed     Abstract available
    
    
    
83. WANG G, Verma AK, Guan X, Bu F, et al
    Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.
    J Virol. 2024 Aug 27:e0037624. doi: 10.1128/jvi.00376.
    PubMed     Abstract available
    
    
    
84. UNO N, Ebensen T, Guzman CA, Ross TM, et al
    Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses.
    J Virol. 2024 Aug 22:e0035424. doi: 10.1128/jvi.00354.
    PubMed     Abstract available
    
    
    
85. MOSS WJ, Griffin DE
    What's going on with measles?
    J Virol. 2024;98:e0075824.
    PubMed     Abstract available
    
    
    
86. LI J, Xiao L, Chen Z, Fan L, et al
    A spike-based mRNA vaccine that induces durable and broad protection against porcine deltacoronavirus in piglets.
    J Virol. 2024 Aug 19:e0053524. doi: 10.1128/jvi.00535.
    PubMed     Abstract available
    
    
    
87. MU Z, Whitley J, Martik D, Sutherland L, et al
    Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.
    J Virol. 2024 Aug 13:e0013724. doi: 10.1128/jvi.00137.
    PubMed     Abstract available
    
    
    July 2024
88. WIGGINS KB, Winston SM, Reeves IL, Gaevert J, et al
    rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single dose.
    J Virol. 2024 Jul 30:e0078124. doi: 10.1128/jvi.00781.
    PubMed     Abstract available
    
    
    
89. NELSON GW, van Duijn J, Yuki Y, Pau MG, et al
    Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.
    J Virol. 2024 Jul 24:e0028124. doi: 10.1128/jvi.00281.
    PubMed     Abstract available
    
    
    
90. LINGEMANN M, Amaro-Carambot E, Lamirande EW, Pierson TC, et al
    Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles.
    J Virol. 2024;98:e0068124.
    PubMed     Abstract available
    
    
    
91. PORTUGAL R, Goldswain H, Moore R, Tully M, et al
    Six adenoviral vectored African swine fever virus genes protect against fatal disease caused by genotype I challenge.
    J Virol. 2024;98:e0062224.
    PubMed     Abstract available
    
    
    
92. KOTAKI T, Kanai Y, Onishi M, Minami S, et al
    Generation of single-round infectious rotavirus with a mutation in the intermediate capsid protein VP6.
    J Virol. 2024;98:e0076224.
    PubMed     Abstract available
    
    
    
93. MCMILLEN CM, Megli C, Radisic R, Skvarca LB, et al
    Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface.
    J Virol. 2024 Jul 17:e0098324. doi: 10.1128/jvi.00983.
    PubMed     Abstract available
    
    
    
94. ZHANG L, Yu R, Wang L, Zhang Z, et al
    Serial cell culture passaging in vitro led to complete attenuation and changes in the characteristic features of a virulent porcine deltacoronavirus strain.
    J Virol. 2024 Jul 16:e0064524. doi: 10.1128/jvi.00645.
    PubMed     Abstract available
    
    
    
95. RICHARDSON SI, Mzindle N, Motlou T, Manamela NP, et al
    SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcgammaRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    J Virol. 2024 Jul 2:e0067824. doi: 10.1128/jvi.00678.
    PubMed     Abstract available
    
    
    June 2024
96. ZHU J, Wang Z, Li Y, Zhang Z, et al
    Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    J Virol. 2024 Jun 14:e0052124. doi: 10.1128/jvi.00521.
    PubMed     Abstract available
    
    
    
97. BOOPATHY AV, Nekkalapudi A, Sung J, Schulha S, et al
    Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.
    J Virol. 2024 Jun 3:e0029424. doi: 10.1128/jvi.00294.
    PubMed     Abstract available
    
    
    
98. LU J, Liu J, Wu Y, He X, et al
    A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses.
    J Virol. 2024 Jun 3:e0076924. doi: 10.1128/jvi.00769.
    PubMed     Abstract available
    
    
    May 2024
99. CARTER DM, Darby CA, Lefoley BC, Crevar CJ, et al
    Correction for Carter et al., "Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses".
    J Virol. 2024 May 31:e0181323. doi: 10.1128/jvi.01813.
    PubMed    
    
    
    
100. DOETS K, Pijlman GP
     Subgenomic flavivirus RNA as key target for live-attenuated vaccine development.
     J Virol. 2024 May 29:e0010023. doi: 10.1128/jvi.00100.
     PubMed     Abstract available
     
     
     
101. HASHIZUME M, Takashima A, Iwasaki M
     An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
     J Virol. 2024 May 20:e0057824. doi: 10.1128/jvi.00578.
     PubMed     Abstract available
     
     
     April 2024
102. THORESEN D, Matsuda K, Urakami A, Ngwe Tun MM, et al
     A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.
     J Virol. 2024 Apr 22:e0023924. doi: 10.1128/jvi.00239.
     PubMed     Abstract available
     
     
     
103. FAN Y-C, Chen J-M, Chen Y-Y, Ke Y-D, et al
     Epitope(s) involving amino acids of the fusion loop of Japanese encephalitis virus envelope protein is(are) important to elicit protective immunity.
     J Virol. 2024;98:e0177323.
     PubMed     Abstract available
     
     
     
104. PEREZ DR
     A devastating blow: personal reflections on Argentina's scientific decline.
     J Virol. 2024 Apr 16:e0054924. doi: 10.1128/jvi.00549.
     PubMed     Abstract available
     
     
     
105. ISHIMARU H, Nishimura M, Shigematsu H, Marini MI, et al
     Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
     J Virol. 2024 Apr 16:e0041624. doi: 10.1128/jvi.00416.
     PubMed     Abstract available
     
     
     
106. TANG X, Li S, Zhou J, Bian X, et al
     Recombinant bivalent subunit vaccine combining truncated VP4 from P[7] and P[23] induces protective immunity against prevalent porcine rotaviruses.
     J Virol. 2024 Apr 9:e0021224. doi: 10.1128/jvi.00212.
     PubMed     Abstract available
     
     
     
107. QUADIRI A, Prakash S, Dhanushkodi NR, Singer M, et al
     Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4(+) and CD8(+) T cells and protects against recurrent
     J Virol. 2024 Apr 8:e0159623. doi: 10.1128/jvi.01596.
     PubMed     Abstract available
     
     
     
108. MANTEL N, Piras-Douce F, Chautard E, Marcos-Lopez E, et al
     Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
     J Virol. 2024 Apr 3:e0151623. doi: 10.1128/jvi.01516.
     PubMed     Abstract available
     
     
     
109. BRUNET J, Choucha Z, Gransagne M, Tabbal H, et al
     A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
     J Virol. 2024 Apr 2:e0169323. doi: 10.1128/jvi.01693.
     PubMed     Abstract available
     
     
     
110. NAMBULLI S, Escriou N, Rennick LJ, Demers MJ, et al
     A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
     J Virol. 2024 Apr 2:e0176223. doi: 10.1128/jvi.01762.
     PubMed     Abstract available
     
     
     
111. ZHU Z, Han Y, Gong M, Sun B, et al
     Establishment of replication-competent vesicular stomatitis virus recapitulating SADS-CoV entry.
     J Virol. 2024 Apr 1:e0195723. doi: 10.1128/jvi.01957.
     PubMed     Abstract available
     
     
     March 2024
112. WU K, Hou YJ, Makrinos D, Liu R, et al
     Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
     J Virol. 2024 Mar 25:e0160323. doi: 10.1128/jvi.01603.
     PubMed     Abstract available
     
     
     
113. NUNBERG JH, Westover JB, York J, Jung KH, et al
     Restoration of virulence in the attenuated Candid#1 vaccine virus requires reversion at both positions 168 and 427 in the envelope glycoprotein GPC.
     J Virol. 2024 Mar 20:e0011224. doi: 10.1128/jvi.00112.
     PubMed     Abstract available
     
     
     
114. MAI F, Bergmann W, Reisinger EC, Muller-Hilke B, et al
     The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection.
     J Virol. 2024 Mar 19:e0191223. doi: 10.1128/jvi.01912.
     PubMed     Abstract available
     
     
     February 2024
115. GEORGANA I, Scutts SR, Gao C, Lu Y, et al
     Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus protein C4.
     J Virol. 2024 Feb 27:e0148523. doi: 10.1128/jvi.01485.
     PubMed     Abstract available
     
     
     
116. JOSHI VR, Claiborne DT, Pack ML, Power KA, et al
     A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
     J Virol. 2024 Feb 27:e0172023. doi: 10.1128/jvi.01720.
     PubMed     Abstract available
     
     
     
117. KATAYAMA M, Murakami S, Ishida H, Matsugo H, et al
     Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein among influenza D virus lineages revealed using epitope mapping.
     J Virol. 2024 Feb 12:e0190823. doi: 10.1128/jvi.01908.
     PubMed     Abstract available
     
     
     
118. SHINGAI M, Iida S, Kawai N, Kawahara M, et al
     Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire.
     J Virol. 2024 Feb 7:e0199523. doi: 10.1128/jvi.01995.
     PubMed     Abstract available
     
     
     
119. LI H, Sun H, Tao M, Han Q, et al
     Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
     J Virol. 2024 Feb 2:e0112923. doi: 10.1128/jvi.01129.
     PubMed     Abstract available
     
     
     
120. HSIEH M-S, Hsu C-W, Liao H-C, Lin C-L, et al
     SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
     J Virol. 2024 Feb 1:e0154623. doi: 10.1128/jvi.01546.
     PubMed     Abstract available
     
     
     January 2024
121. ROWE T, Davis W, Wentworth DE, Ross T, et al
     Differential interferon responses to influenza A and B viruses in primary ferret respiratory epithelial cells.
     J Virol. 2024 Jan 31:e0149423. doi: 10.1128/jvi.01494.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.